Literature DB >> 7927165

The pharmaceutical industry and health reform: lessons from Europe.

J Hutton, M Borowitz, I Oleksy, B R Luce.   

Abstract

Many countries in Europe, which have significant pharmaceutical industries, recently have embarked on reforms in the organization of their health care systems and methods of regulating the pharmaceutical market. This paper describes the different systems in major European countries and the changes taking place. Although it is too early to make final judgment on the impact of these changes, it is possible to predict some of the more likely outcomes. The organizational models and regulatory approaches in Europe offer a useful store of experience for those assessing the potential impact of reform proposals in the United States.

Mesh:

Year:  1994        PMID: 7927165     DOI: 10.1377/hlthaff.13.3.98

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  5 in total

1.  Health care expenditure inertia in the OECD countries: a heterogeneous analysis.

Authors:  A A Okunade; C Suraratdecha
Journal:  Health Care Manag Sci       Date:  2000-01

2.  Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry.

Authors:  K Bloor; A Maynard; N Freemantle
Journal:  BMJ       Date:  1996-07-06

3.  Promoting cost effective prescribing.

Authors:  N Freemantle; D Henry; A Maynard; G Torrance
Journal:  BMJ       Date:  1995-04-15

4.  Equivalence and noninferiority trials - are they viable alternatives for registration of new drugs? (III).

Authors:  Cornel Pater
Journal:  Curr Control Trials Cardiovasc Med       Date:  2004-08-17

Review 5.  International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review.

Authors:  Iyn-Hyang Lee; Karen Bloor; Catherine Hewitt; Alan Maynard
Journal:  J Health Serv Res Policy       Date:  2014-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.